Overview

A Study to Evaluate the Safety and Efficacy of PF-06650833, PF-06700841, and PF 06826647 in Adults With Hidradenitis Suppurativa

Status:
Active, not recruiting

Trial end date:
2022-01-06

Target enrollment:

Participant gender:

Summary

This is a study with 3 kinase inhibitors (PF 06650833, PF 06700841 and PF 06826647) in participants with moderate to severe HS. The study will have a maximum duration of approximately 26 weeks. This includes an up to 6-week Screening Period, a 16 week Dosing Period and a 4 week Follow up Period.

Phase:

Phase 2

Details

Lead Sponsor:

Pfizer

Treatments:

PF-06700841